Kura Oncology, Inc.KURANASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank82
3Y CAGR+37.0%
5Y CAGR+3.7%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+37.0%/yr
vs -19.9%/yr prior
5Y CAGR
+3.7%/yr
Recent acceleration
Acceleration
+56.9pp
Accelerating
Percentile
P82
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 19.18% |
| Q3 2025 | 30.47% |
| Q2 2025 | 10.22% |
| Q1 2025 | -5.13% |
| Q4 2024 | 32.41% |
| Q3 2024 | 10.34% |
| Q2 2024 | -8.22% |
| Q1 2024 | 28.08% |
| Q4 2023 | 8.40% |
| Q3 2023 | 9.37% |
| Q2 2023 | 3.93% |
| Q1 2023 | -8.92% |
| Q4 2022 | 7.46% |
| Q3 2022 | 4.93% |
| Q2 2022 | -6.69% |
| Q1 2022 | -1.76% |
| Q4 2021 | 6.83% |
| Q3 2021 | -10.05% |
| Q2 2021 | 18.93% |
| Q1 2021 | 20.03% |
| Q4 2020 | 16.00% |
| Q3 2020 | 1.57% |
| Q2 2020 | -1.95% |
| Q1 2020 | 38.66% |
| Q4 2019 | 7.11% |
| Q3 2019 | 15.34% |
| Q2 2019 | -2.58% |
| Q1 2019 | 0.42% |
| Q4 2018 | 5.30% |
| Q3 2018 | 13.71% |
| Q2 2018 | 10.95% |
| Q1 2018 | 19.09% |
| Q4 2017 | 22.02% |
| Q3 2017 | 3.47% |
| Q2 2017 | 6.45% |
| Q1 2017 | 8.35% |
| Q4 2016 | 13.38% |
| Q3 2016 | -6.09% |
| Q2 2016 | -22.42% |
| Q1 2016 | 38.29% |